e-Drug3D

1745

PALBOCICLIB

INN
PALBOCICLIB

cas 571190-30-2

CLASS

ANTINEOPLASTIC
TREATMENT OF BREAST CANCER
CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS

ROUTE (list)

ORAL

ATC code

L01EF01

PK parameters

F 46 PERCENT
Tmax 9 HOUR
VD 2583 LITER
Cl 63.1 LITER / HOUR
PPB 85 PERCENT
t1/2 29 HOUR

Solubility

ABOVE PH4 THE SOLUBILITY REDUCES SIGNIFICANTLY

Target

TARGET CYCLIN-DEPENDENT KINASE (CDK) 4
CYCLIN-DEPENDENT KINASE (CDK) 6

PDB
2EUF (X-RAY STRUCTURE OF HUMAN CDK6-VCYCLIN IN COMPLEX WITH THE INHIBITOR PD0332991)

Ligand code = LQQ (link to the list of PDB complexes)

Download experimental 3D coordinates of LQQ with added hydrogens

DrugCentral

Cyclin-dependent kinase 6 UNIPROT Q00534 CDK6

Cyclin-dependent kinase 4 UNIPROT P11802 CDK4

Download SDF file

Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-acetyl-8-cyclopentyl-5-methyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-

Formula:
C24H29N7O2

Calculated chemical properties:

MW 447.54
NB_atoms 33
XLogP 2.97
PSA 90.595
NB_HD 2
NB_HA 9
fsp3 0.46
Lipinski(0=no;1=yes) 1

FDA
NDA 207103 (pdf not found) INN (PALBOCICLIB) IBRANCE (PFIZER) APPROVAL= AP YEAR= 2015
NDA 212436 (pdf not found) INN (PALBOCICLIB) IBRANCE (PFIZER) APPROVAL= AP YEAR= 2019
NDA 213107 (pdf not found) INN (PALBOCICLIB) PALBOCICLIB (SUN PHARM INDS LTD) APPROVAL= TA YEAR= 2021
NDA 213091 (pdf not found) INN (PALBOCICLIB) PALBOCICLIB (DR REDDYS LABS LTD) APPROVAL= TA YEAR= 2021
NDA 213086 (pdf not found) INN (PALBOCICLIB) PALBOCICLIB (EUGIA PHARMA SPECLTS) APPROVAL= TA YEAR= 2022
NDA 213152 (pdf not found) INN (PALBOCICLIB) PALBOCICLIB (AIZANT DRUG RESEARCH SOLUTIONS PVT LTD) APPROVAL= TA YEAR= 2022
NDA 214758 (pdf not found) INN (PALBOCICLIB) PALBOCICLIB (MSN PHARMACEUTICALS INC) APPROVAL= TA YEAR= 2023
NDA 215570 (pdf not found) INN (PALBOCICLIB) PALBOCICLIB (ZYDUS LIFESCIENCES) APPROVAL= AP YEAR= 2024 DISCONTINUED